Mabwell (688062.SH), a biopharmaceutical company, announced on Friday that it has received Fast Track Designation (FTD) from the US Food and Drug Administration (FDA) for its self-developed novel Nectin-4-targeting ADC (R&D Code: 9MW2821) intended to treat locally advanced or metastatic Nectin-4 positive triple negative breast cancer (TNBC).
This move is aimed at accelerating the development and review of pharmaceuticals used to treat critical conditions, therefore lowering the time required to bring these drugs to market.
The product has received multiple regulatory designations from the FDA within the last six months. Previously, the product received FTD for the treatment of advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC) and recurrent or metastatic cervical cancer (CC) progressed on or subsequent to prior treatment with a platinum-based chemotherapy regimen, and also received Orphan Drug Designation (ODD) for the treatment of esophageal cancer (EC).
Quest Diagnostics acquires OhioHealth lab assets
Exelixis and Merck collaborate on clinical development of zanzalintinib
BD launches automated reagent kit to streamline single-cell discovery studies
Transgene's Phase II trial of TG4001 falls short of primary objective
SkylineDx reveals new data from the MERLIN_001 prospective US multi-centre trial
Turnstone Biologics announces strategic restructuring
Pfizer's TALZENNA plus XTANDI shows promise in prostate cancer treatment
GenesisCare UK selects RayStation for radiotherapy system upgrade
Boehringer Ingelheim and Circle Pharma collaborate on cancer treatment
Petauri launches medical communications platform Petauri Advance
Bayer and MOMA Therapeutics enter oncology collaboration
GBI Biomanufacturing agrees manufacturing collaboration with Allterum Therapeutics
MediLink enters clinical trial collaboration and supply agreement with Amgen